Pyxis Oncology, Inc.
Income Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $13.9M | $16.1M |
| Cost of Revenue | $2.4M | $475.0K |
| Gross Profit | $11.5M | $15.7M |
| Gross Margin | 82.8% | 97.1% |
| Operating Expenses | ||
| Research & Development | $73.7M | $58.7M |
| SG&A Expense | $22.2M | $25.4M |
| Operating Income | $-84.4M | $-89.5M |
| Operating Margin | -609.2% | -554.1% |
| Interest Expense | — | — |
| Pretax Income | $-78.2M | $-79.5M |
| Income Tax Expense | $1.4M | $-2.2M |
| Net Income | $-79.6M | $-77.3M |
| Net Margin | -574.5% | -478.9% |
| EPS (Basic) | $-1.28 | $-1.32 |
| EPS (Diluted) | $-1.28 | $-1.32 |
| Shares Outstanding (Basic) | 62.1M | 58.4M |
| Shares Outstanding (Diluted) | 62.1M | 58.4M |
| Dividends Per Share | — | — |